Contract Research

Merck’s Cancer Drug Keytruda Notches Another Trial Success

May 24, 2018

(Reuters) – Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.   Keytruda, already approved for other types of cancer, is being studied in a late-stage trial as […]

Novotech says Federal Budget R&D Tax Support Keeps Australia Globally Competitive for Quality Clinical Trials

May 20, 2018

SYDNEY, AUS, May 21, 2018 – (ACN Newswire) – Leading Asia Pacific CRO Novotech commended the Turnbull Government’s Federal Budget decision to exclude clinical trials activity from a A$4m cap on cash refunds, or any lifetime cap on refunds. Novotech CEO Dr John Moller said the move reaffirms Australian’s lead position in attracting foreign investment for drug development and […]

Internationalisation and regulatory reform driving growth and investment at CPhI China

May 18, 2018

Amsterdam, 17 May 2018: CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018. Asia’s largest pharmaceutical event returns with recent regulatory reforms stimulating international interest in the region, as the CFDA is harmonising China’s regulatory environment with the rest […]

Envision Pharma Group announces the successful implementation of iEnvision to connect and support Otsuka’s medical affairs activities

May 15, 2018

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) has completed the first phase of implementation of the iEnvision medical affairs platform developed by Envision Technology Solutions, part of Envision Pharma Group. iEnvision is a web-based software platform specifically designed and developed to support multiple medical affairs-related programs of activity. Otsuka is deploying iEnvision to manage several […]

ERT Improves Efficiency of Multiple Sclerosis Trials

May 14, 2018

ERT Improves Efficiency of Multiple Sclerosis Trials Industry’s only electronic Neurostatus-EDSS® System with full scoring algorithms and complete data checks ensures data quality PHILADELPHIA – May 14, 2018 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the availability of the ERT Neurostatus-EDSS System. The complete […]

Setback To Roche Hopes For Tecentriq As Fails Key Cancer Trial

May 10, 2018

ZURICH (Reuters) – Roche’s hopes of its Tecentriq immunotherapy catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial. Roche was evaluating Tecentriq and its targeted drug Cotellic against colorectal cancer, a big market with some 1.4 million new cases diagnosed globally in 2012 […]

Clinipace Worldwide Names Charlene Dark Vice President, Global Clinical Analytics

May 10, 2018

Morrisville, N.C., May 10, 2018 (BUSINESS WIRE) — Clinipace Worldwide, a global full-service clinical research organization (CRO), has announced the appointment of Charlene Dark as vice president, global clinical analytics. In her role, Dark will be responsible for operational and commercial delivery of Clinipace’s data management, biostatistics and statistical programming functions.   Dark is a […]

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

May 8, 2018

SHANGHAI, May 8, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration (FDA) – with no Form 483s issued. This is the first time that […]

Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial

May 3, 2018

HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq:MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has […]

WuXi STA to build new R&D center in Shanghai

April 27, 2018

SHANGHAI, April 27, 2018: STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center. The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate […]

FEEDBACK